Editas Medicine (EDIT) Tops Q3 EPS by 5c

Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.59), $0.05 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $962 thousand versus the consensus estimate of $960 thousand.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• CVG to join Russell 2000 and Russell 3000 indexes June 26
• Nike names former Pfizer CFO David Denton as new finance chief